FindTrial
Sign In

NeisVac-C™

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniHaemophilus Influenzae Type bHepatitis BNeisseria MeningitidisPoliomyelitisTetanus

Phase 2

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose
CompletedNCT01171989
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni +4
Start: 2010-08-18End: 2010-12-03Updated: 2020-01-21

Phase 3

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC
CompletedNCT00322335
GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis
Start: 2006-05-31End: 2010-09-30Updated: 2016-10-20

Related Papers

A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
2013-07-016 citations